The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Multiple Sclerosis and Neuroimmunology
Volume 16 - 2025 |
doi: 10.3389/fimmu.2025.1505459
This article is part of the Research Topic Exploring the Immunopathogenesis of Multiple Sclerosis and Axonal Injuries: Unveiling Potential Therapeutic Targets and Strategies for the Development of Innovative Treatments View all articles
Proteomic analysis reveals candidate molecules to mediate cortical pathology and identify possible biomarkers in an animal model of Multiple Sclerosis
Provisionally accepted- 1 IIBBA-CONICET Leloir Institute Foundation, Buenos Aires, Buenos Aires, Argentina
- 2 Fundación para el Progreso de la Medicina, Córdoba, Córdoba, Argentina
Multiple Sclerosis (MS) is a complex neurodegenerative disease marked by recurring inflammatory episodes, demyelination, axonal damage, and subsequent loss of function. MS presents a wide range of clinical courses, with the progressive forms leading to irreversible neurological disability. Cortical demyelinating lesions are central to the pathology of these progressive forms, gaining critical importance in recent decades due to their strong correlation with physical disability and cognitive decline. Despite this, the underlying mechanisms driving cortical lesion formation remain poorly understood, and no specific treatments are currently available. A significant challenge lies in the lack of animal models that accurately mirror the key characteristics of these lesions. To address this, we developed a focal cortical animal model that replicates many features of cortical lesions, including cognitive impairment. This study focuses on conducting proteomic analyses of both the cortical lesions and cerebrospinal fluid (CSF) from these animals, aiming to identify key proteins and biomarkers that could be validated in MS patients. We observed proteomic differences between frontal cortex tissue and CSF when comparing experimental animals with controls. Among the identified proteins, some have been previously described in MS patients and animal models, while others represent novel discoveries. Notably, we identified two proteins, S100A8 and orosomucoid-1, that were highly expressed in both regions. These findings suggest that the prognostic molecules identified in this model could facilitate the discovery of new biomarkers or key molecules relevant to MS, particularly in the cortical lesion that mainly characterized the progressive forms of the disease.
Keywords: Cortex, Cerebrospinal Fluid, interleukin-1β, demyelination, neurodegeneration, Neuroinflammation, Orosomucoid-1, S100A8
Received: 02 Oct 2024; Accepted: 15 Jan 2025.
Copyright: © 2025 Silva, Leal, Farias, Nava, Galvan, Fernandez, PITOSSI and Ferrari. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Carina Cintia Ferrari, IIBBA-CONICET Leloir Institute Foundation, Buenos Aires, 1405, Buenos Aires, Argentina
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.